For instance, several clinical studies have shown the efficacy of obeticholic acid (OCA), an FXR agonist, in the improvement of insulin sensitivity, liver histology, hepatic inflammation, and fibrosis.[49, 50, 51] In this study, we for the first time, to our knowledge, uncovered an NR2F6/CD36 axis that plays a role for obesity‐associated NAFLD. This evidence concerns the gene NR2F6 and metabolic dysfunction-associated steatotic liver disease.